Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Neurological Medicine
Volume 2014 (2014), Article ID 191305, 4 pages
http://dx.doi.org/10.1155/2014/191305
Case Report

Intermittent Atrioventricular Block following Fingolimod Initiation

Department of Neurology, Athens National and Kapodistrian University, “Aeginition” Hospital, 11528 Athens, Greece

Received 13 April 2014; Accepted 14 July 2014; Published 5 August 2014

Academic Editor: Isabella Laura Simone

Copyright © 2014 E. Gialafos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Willis and J. A. Cohen, “Fingolimod for multiple sclerosis,” Seminars in Neurology, vol. 33, pp. 37–44, 2013. View at Google Scholar
  2. R. Gold, G. Comi, J. Palace et al., “FIRST Study Investigators. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study,” Journal of Neurology, vol. 261, no. 2, pp. 267–276, 2014. View at Google Scholar
  3. L. Koyrakh, M. I. Roman, V. Brinkmann, and K. Wickman, “The heart rate decrease caused by the sphingosine 1-phosphate receptor agonist FTY720 results from activation of the G protein-gated potassium channel IKACh,” The American Journal of Transplantation, vol. 5, no. 3, pp. 529–536, 2005. View at Publisher · View at Google Scholar
  4. M. G. Sanna, J. Liao, E. Jo et al., “Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate,” The Journal of Biological Chemistry, vol. 279, no. 14, pp. 13839–13848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. P. S. Espinosa and J. R. Berger, “Delayed fingolimod-associated asystole,” Multiple Sclerosis, vol. 17, no. 11, pp. 1387–1389, 2011. View at Google Scholar
  6. J. W. Lindsey, K. Haden-Pinneri, N. B. Memon, and L. M. Buja, “Sudden unexpected death on fingolimod,” Multiple Sclerosis, vol. 18, no. 10, pp. 1507–1508, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Faber, H. J. Fischer, and F. Weber, “Prolonged and symptomatic bradycardia following a single dose of fingolimod,” Multiple Sclerosis, vol. 19, no. 1, pp. 126–128, 2013. View at Publisher · View at Google Scholar
  8. B. Olshansky, H. N. Sabbah, P. J. Hauptman, and W. S. Colucci, “Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy,” Circulation, vol. 118, no. 8, pp. 863–871, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. K. G. Lehmann, J. G. Lane, J. M. Piepmeier, and W. P. Batsford, “Cardiovascular abnormalities accompanying acute spinal cord injury in humans: incidence, time course and severity,” Journal of the American College of Cardiology, vol. 10, no. 1, pp. 46–52, 1987. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Lalouschek, C. Müller, G. Gamper, M. Weissel, and K. Turetschek, “Myocardial ischemia with normal coronary arteries associated with thoracic myelitis,” New England Journal of Medicine, vol. 337, no. 26, p. 1920, 1997. View at Publisher · View at Google Scholar · View at Scopus